Atossa Genetics (ATOS) Stock Price, News & Analysis

Company Overview

Atossa Genetics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer. The company’s research is centered on precision medicines intended to address unmet needs in breast cancer treatment and prevention.

Atossa’s leading development program is oral endoxifen, an active metabolite of tamoxifen and a selective estrogen receptor modulator. The company is evaluating endoxifen in clinical studies involving hormone receptor-positive breast cancer, including settings before surgery and in patients who may benefit from reducing tumor activity or breast cancer risk.

Founded in 2009 and headquartered in Seattle, Washington, Atossa initially pursued diagnostic products for breast health before concentrating its business on therapeutic development. The company serves the global biopharmaceutical and medical research markets through its clinical programs and collaborations. Steven Quay, M.D., Ph.D., is the company’s founder and chief executive officer.

Key Stats

• Today's Range: $2.12 to $2.74
• 50-Day Range: $1.90 to $2.79
• 52-Week Range: $1.70 to $18.00
• Volume: 265,555 shs
• Average Volume: 66,357 shs
• Market Capitalization: $24.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.33
• Consensus Rating: Hold

Atossa Genetics Stock Analysis - MarketRank™

Atossa Genetics scored higher than 47% of companies evaluated by MarketBeat, and ranked 557th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Hold

Consensus Rating

Atossa Genetics has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 2 sell ratings.

Upside Potential

Atossa Genetics has a consensus price target of $20.33, representing about 733.3% upside from its current price of $2.44.

Amount of Analyst Coverage

Atossa Genetics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Atossa Genetics are expected to grow in the coming year, from ($3.75) to ($2.78) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Atossa Genetics is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Atossa Genetics is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Atossa Genetics has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.76% of the float of Atossa Genetics has been sold short.

Short Interest Ratio / Days to Cover

Atossa Genetics has a short interest ratio ("days to cover") of 11.31, which indicates bearish sentiment.

Change versus previous month

Short interest in Atossa Genetics has recently increased by 3.43%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Atossa Genetics does not currently pay a dividend.

Dividend Growth

Atossa Genetics does not have a long track record of dividend growth.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: 0.80

News Sentiment

Atossa Genetics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Atossa Genetics this week, compared to 3 articles on an average week.

Search Interest

7 people have searched for ATOS on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.

MarketBeat Follows

3 people have added Atossa Genetics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Atossa Genetics insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.80% of the stock of Atossa Genetics is held by insiders.

Percentage Held by Institutions

12.74% of the stock of Atossa Genetics is held by institutions.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 10/09/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ATOS
• CIK: 1488039
• Web: atossatherapeutics.com
• Phone: (206) 588-0256
• Fax: 206-430-1288
• Employees: 14
• Year Founded: 2009

Price Target and Rating

• Average Price Target for Atossa Genetics: $20.33
• High Price Target: $25.00
• Low Price Target: $12.00
• Potential Upside/Downside: +733.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$34.77 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -102.99%
• Return on Assets: -85.78%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.69
• Quick Ratio: 5.69

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.57 per share
• Price / Book: 0.53

Miscellaneous

• Outstanding Shares: 9,980,000
• Free Float: 9,001,000
• Market Cap: $24.35 million
• Optionable: Optionable
• Beta: 1.27